A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors
Latest Information Update: 22 Apr 2025
At a glance
- Drugs BCG 011 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Xadcera Biopharmaceutical (Suzhou)
Most Recent Events
- 30 Oct 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2024 to 22 Oct 2024.
- 30 Oct 2024 Status changed from not yet recruiting to recruiting.
- 02 Jul 2024 New trial record